Patents Represented by Attorney The McCallum Law Firm, P.C.
-
Patent number: 8084533Abstract: The present invention provides the use of a particulate polymer material as a support for an active agent, characterized in that said polymer material is a polymer produced by copolymerizing an unsaturated heterocyclic monomer and squaric or croconic acid or a derivative thereof.Type: GrantFiled: May 5, 2005Date of Patent: December 27, 2011Inventor: Daniel Eric Lynch
-
Patent number: 8017374Abstract: The present invention relates to a novel process for decolorization of colored effluents. More particularly it relates to a process for decolorization of colored effluents of textile mills, dye-making industries, paper and pulp industries and molasses spent wash from alcohol distilleries using an unidentified white-rot marine fungus NIOCC #2a isolated from mangrove wood and deposited on Sep. 7, 2004 in the microbial type culture collection (MTCC) of the Institute of Microbial Technology, Chandigarh, India, under the accession number MTCC 5159. Further, this invention relates to decolorization of these effluents using the fungus directly, its cell-free culture supernatant or immobilized fungus or extracellular polymeric substances produced by the fungus. Furthermore, the decolorization of effluents can be carried out from 30° C. to 60° C. and at pH 3 to 6. The decolorization of various colored effluents occurs in the presence of sea water with 25 parts per thousand salinity.Type: GrantFiled: February 12, 2005Date of Patent: September 13, 2011Assignee: Council of Scientific and Industrial ResearchInventors: Chandralata Raghu Kumar, Donna Trella D'Souza Ticlo
-
Patent number: 7989663Abstract: Fluorogenic lysophosphatidic acid derivatives which can be used as substrates in a continuous, fluorogenic assay that can be performed in microtiter plates. The assays permit measuring LysoPLD activity levels in normal events such as pregnancy or disease states such as cancer. In addition, the present invention can be adopted to high throughout screening (HTS) for identification of potential inhibitors of lysoPLD activity.Type: GrantFiled: October 28, 2008Date of Patent: August 2, 2011Assignee: Echelon Biosciences IncorporatedInventors: Colin Ferguson, Glenn Prestwich
-
Patent number: 7833704Abstract: The present invention provides a method for the detection and sorting of microparticles in a mixture of microparticles. The method of the present invention allows for the detection and sorting of many distinct microparticle classes. Detection and sorting is on the basis of microparticle size, the fluorescence spectrum of any attached reporter molecule, the fluorescence intensity of the reporter molecule, and the number of particles in each classification bin. These microparticle classes have particular applications in many genetic or biochemical multiplexing studies and especially as binding agents for the detection of aneuploidy in an organism or embryo of the organism.Type: GrantFiled: July 2, 2004Date of Patent: November 16, 2010Assignee: Genera Biosystems LimitedInventors: Andrew Patrick Wildenberg, Karl Poetter
-
Patent number: 7459285Abstract: Fluorogenic lysophosphatidic acid derivatives which can be used as substrates in a continuous, fluorogenic assay that can be performed in microtiter plates. The assays permit measuring LysoPLD activity levels in normal events such as pregnancy or disease states such as cancer. In addition, the present invention can be adopted to high throughout screening(HTS) for identification of potential inhibitors of lysoPLD activity.Type: GrantFiled: December 9, 2003Date of Patent: December 2, 2008Assignee: Echelon Biosciences IncorporatedInventors: Colin Ferguson, Glenn Prestwich
-
Patent number: 7407777Abstract: Compounds, genetic constructs, and cancer treatment methods are provided. Expression vectors were designed to express fusion genes including hIL-2 with a Fc?-? transmembrane anchor derived from a subunit of the FC epsilon receptor. mRNA and the IL-2tm fusion protein was expressed in transfected RD995 tumor cells. Expression of the IL-2tm protein on the tumor cell surface membrane was confirmed by microscopy. RD995 cells transfected with IL-2tm or pCMV2b (empty expression vector) were implanted subcutaneously into C3H/HEN mice. Tumors of mice implanted with 106 or 105 RD995 cells transfected with IL-2tm grew slower than controls. It is believed that selective expression of cytokines such as IL-2 on the surface of tumors is likely to stimulate tumor-infiltrating lymphocytes that are primed and already recognize tumor antigens, enhancing tumor recognition and killing, potentially avoiding toxicity associated with known cytokine therapies.Type: GrantFiled: March 8, 2004Date of Patent: August 5, 2008Assignee: University of Utah Research FoundationInventors: Wolfram Samlowski, Nathan Bradley Adams, John McGregor
-
Patent number: 7407752Abstract: The methods disclosed herein are of use for the treatment of a wide variety of diseases. In particular, the methods provide for the targeting of a transcription altering agent to a specific target site of a viral genome in order to inactivate the virus. In addition, the methods provide for a triplex-forming oligonucleotide capable of interacting with a target site in a viral genome in order to alter transcription. The methods of the present invention may be used against viral pathogens or agents of bioterrorism.Type: GrantFiled: April 21, 2004Date of Patent: August 5, 2008Assignees: University of Utah Research Foundation, Yale UniversityInventors: John D. Kriesel, Brandt B. Jones, Charles B. Grissom, Geoff Herpin, Peter M. Glazer
-
Patent number: 7244562Abstract: A method for detecting a specific sequence, a mutation and/or a polymorphisms, including a single nucleotide polymorphism (SNP), is based on the use of RecA-like recombinase protein and primer extension (PE) or oligonucleotide ligation assays (OLA). RecA coated, specific DNA oligonucleotide probes (RecA filaments) are used for homology searching in duplex DNA. Location of homologous sequences results in the formation of D-loop or double D-loop structures containing a duplex regions comprising the oligonucleotide probe and one strand of the target DNA. In the case of the PE methods, probes are selected to terminate with their 3? end adjacent to the site of mutation or SNP such that a single nucleotide or terminator addition to the primer will be diagnostic of the mutation or SNP.Type: GrantFiled: October 30, 2002Date of Patent: July 17, 2007Assignee: Gene Check, Inc.Inventor: Robert E. Wagner, Jr.
-
Patent number: 7192941Abstract: Methods are provided for the treatment of pulmonary hypertension and other conditions associated therewith. In particular, the methods include treatment of pulmonary hypertension with estradiol metabolite or estradiol metabolite associated with biodegradable microparticles or nanoparticles alone or in combination with another therapeutic agent. Preferred estradiol metabolites include 2-methoxyestradiol, 4-methoxyestradiol, 2-hydroxyestradiol, and 4-hydroxyestradiol, and/or to synthetic derivatives and analogues thereof or prodrugs thereof. The compositions may also be in the form of a controlled release formulation.Type: GrantFiled: February 20, 2004Date of Patent: March 20, 2007Assignee: University of PittsburghInventors: Stevan P. Tofovic, Edwin K. Jackson